Hoth Therapeutics Completes Closing of Previously Announced $15.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesPRNewsWire • 03/10/21
Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq RulesPRNewsWire • 03/08/21
Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical StudiesPRNewsWire • 03/03/21
Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic DermatitisPRNewsWire • 03/01/21
Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic TreatmentPRNewsWire • 02/26/21
Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's TreatmentPRNewsWire • 02/24/21
Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of HT-001 For Cancer PatientsPRNewsWire • 02/23/21
Hoth Therapeutics Plans To Test HT-003 API In Inflammatory Bowel Disorders; Shares SpikeBenzinga • 02/18/21
Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs)PRNewsWire • 02/18/21
Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxivPRNewsWire • 02/10/21
Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer PatientsPRNewsWire • 02/08/21
Hoth Therapeutics Expands Research Collaboration Agreement with Weill Cornell Medicine to Continue the Advancement of HT-003 for Acne Treatment ResearchPRNewsWire • 01/28/21
Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment IndicationPRNewsWire • 01/20/21
Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer PatientsPRNewsWire • 01/11/21
Hoth Therapeutics Announces Licensing Agreement and Collaboration with U.S. Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung InfectionsPRNewsWire • 01/04/21
Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer PatientsPRNewsWire • 12/23/20
Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in HumansPRNewsWire • 12/10/20
Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin DiseasePRNewsWire • 11/03/20
Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and VaccinePRNewsWire • 11/02/20
Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer TherapeuticPRNewsWire • 10/20/20
Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2)PRNewsWire • 09/24/20
Hoth Therapeutics Enters into Sponsored Research Agreement for On-the-Go COVID-19 Testing DevicePRNewsWire • 09/21/20